Objective. Prednisolone reduced the progression of joint destruction over 2 yr in early, active rheumatoid arthritis. The response to discontinuation of prednisolone under double-blind conditions is now reported.
R arthritis is a major cause of disability, an emergency) the patient codes were not broken until leading to joint destruction and loss of locomotor after the analysis at 36 months. Physicians managing function [1] . Preservation of the articular surfaces is a each patient were free to prescribe any treatment, therapeutic priority, but success in this endeavour has except systemic corticosteroids. After 2 yr, the study been elusive [2, 3] . We have previously reported the medication was reduced to alternate-day treatment for protective effect of 7.5 mg of prednisolone per day on 2 weeks, then every third day treatment for 2 weeks, joint erosions in the hand and wrist in patients with and was then discontinued. Both patient and physician early rheumatoid disease [4] . This effect persisted for therefore remained blind as to the treatment the patient 2 yr, while symptomatic benefit lasted only a few had received. Double-blind follow-up was maintained months, raising the possibility that these two aspects for a further year, and is the subject of this report. of rheumatoid arthritis are related to different patho-
The primary outcome variables were progression of logical mechanisms. We now report on the response of radiological damage in hand radiographs taken at these patients to discontinuation of the study medicaentry and after 1, 2 and 3 yr, and the appearance of tion under double-blind conditions. erosions in hands which had no erosions at baseline. All available radiographs were viewed jointly by the PATIENTS AND METHODS same experienced radiologist and rheumatologist using Full details of the methods of the study have been the same light for all films. To ensure similar conditions published previously [4] . Patients aged 18-69 yr with for assessing radiographs within each patient, and to rheumatoid arthritis of <2 yr duration and currently avoid the possibility of bias which might develop over active disease [defined as six or more painful joints, the several sittings required to read and score the three or more joints with active synovitis, early radiographs, their presentation was in randomly morning stiffness for >20 min and an erythrocyte ordered blocks of 30. All identifying markings were sedimentation rate ( ESR) > 28 mm/h, plasma viscovered. In the initial analysis of response to treatment cosity > 1.72 or C-reactive protein (CRP) > 10 mg/l ] over 2 yr [4] , 0, 1 and 2 yr films from 10 randomly took part. Prednisolone 7.5 mg and identical placebo selected patients were included in each block. Each tablets were prepared and labelled specifically for this hand was classified as erosive or non-erosive and each study. Randomization was in blocks of six subjects joint was then scored by the method of Larsen [5] , within each centre, 13 centres took part and (except in which grades the degree of joint damage on a scale from 0 (radiologically normal joint) to 5 (maximum degree of joint destruction) with reference to a standard coding sheets. The Larsen score is the summation of because they moved away or declined to take study medication). These patients and three others for whom all the joint scores in both hands taken together. In the follow-up analysis of radiographs (which was perthe initial radiographs were lost have been excluded from the analysis. Treatment was discontinued in six formed 14 months after the initial readings), the 2 yr films were re-scored with the 3 yr films to allow for patients (two in the placebo group and one in the prednisolone group for hypertension and weight gain, the possibility of changes in reader sensitivity to identifying radiographic features. Readings were performed and one each in the placebo group for diabetes, starting corticosteroids and declining further medication). in the same way as previously, but the blocks of 30 films contained 2 and 3 yr films for 15 randomly These patients were subsequently followed and included in their initial treatment groups. Thus, 114 selected patients.
Secondary outcomes were assessed every 3 months. radiographs were available at year 0 (53 prednisolone, 61 placebo), but only 110 (53 and 57), 109 (51 and They included changes in disability (measured by the Health Assessment Questionnaire [6 ] ), joint inflam-58) and 96 (44 and 52) were available in subsequent years. mation (measured by an articular index of tender and swollen peripheral joints weighted for joint size [7] ), Re-reading the 2 yr radiographs at the same time as the 3 yr radiographs resulted in adjustments for pain over the previous 24 h (using a visual analogue scale [8] ), and the acute-phase response (measured changes in reader sensitivity as follows: in the prednisolone group, the proportion of hands identified as either by the ESR, CRP or plasma viscosity, depending on the centre). Records of other treatments and adverse erosive in year 3 was reduced by a factor of 0.81, and in the placebo group by a factor of 0.98 (difference reactions (including measurement of weight and blood pressure) were also kept.
0.17, 95% CI 0.04-0.31). In the prednisolone group, the year 3 Larsen score for each patient was reduced Statistical analysis employed the x2 test to compare proportions and Student's t-test to compare means [9] .
by a factor of 0.81 and in the placebo group by a factor of 0.98 (difference 0.17, 95% CI 0.04-0.30). Larsen scores were subject to log transformation [log 10 (score + 1)] before comparison between groups to take These adjusted scores for year 3 were used in all subsequent comparisons and statistical analysis. account of their skewed distribution. Year 3 readings were adjusted to take account of changes in reader
The comparison of radiological progression in all the available radiographs is shown in Table I . This sensitivity as reported below. Overall group mean scores were compared, but a more detailed and exact shows significant benefits for the prednisolone-treated patients at all time points after the initiation of study analysis of radiographic change was conducted on those patients for whom films were available for all
treatment. There appears to be an increase in the difference between the groups during the third year, four time points. The difference in the logarithms between examinations was calculated for each subject.
after study medication has been discontinued. The 75 patients who had radiographs available for all The means of these differences in the two treatment groups were compared and their 95% confidence interfour time points provide a more detailed comparison both within patients and between treatment groups. The vals (CI ) determined using Student's t-test [9] .
Data on secondary outcome variables are presented characteristics of these patients are shown in Table II for the patients for whom films were available for all four time points to allow direct comparison with they were lost to follow-up (three because they were withdrawn with other medical conditions and eight *Antilog of mean after log transformation.
lone-treated patients, there was very little change in the first 2 yr, but a significant increase during year 3, after withdrawing prednisolone treatment. This increase was not significantly different from that in the placebo group during year 3, although by the end of the follow-up period the prednisolone patients still had a much lower Larsen score than the placebo patients (2.29 vs 6.98, P = 0.003). The changes in Larsen score were principally in identifying grade 2 joint changes, and few scores of grade 1 contributed to the total scores. The percentage of hands which had erosions at each time point in the prednisolone group was 27.8, 29.2, 34.7 and 39.2. There was no significant difference between each consecutive time point. Rather, there seemed to be a slowly increasing proportion of erosive F. 1.-Mean (95% CI ) Larsen score after log transformation for hands which did not alter dramatically after discontinu-75 patients with radiographs at all time points. ation of glucocorticoid therapy. The change over the full 3 yr of follow-up was 11.4% (95% CI 4.1-18.7). and compared with the patients excluded from this
In the placebo group, the equivalent figures were 28.2, analysis. There were no significant differences between 48.7 and 59.0 and 66.5. The difference between each prednisolone-and placebo-treated patients, nor between time point was statistically significant (P < 0.05) and patients included and excluded from the analysis. In the pattern follows that which might be expected in particular, the proportions of erosive hands and Larsen these patients [10] . The change over the full 3 yr of scores at baseline were not significantly different.
follow-up was 38.3% (95% CI 27.5-49.1). The overall progression of Larsen scores is shown in Clinically, the 75 patients analysed here reflect the Fig. 1 and Table III. In the placebo group, there was broad picture of the response of all the patients entered into the original study and reported previously. There steadily progressive joint destruction. In the predniso- There are no statistically significant differences between groups at P < 0.05. patients were taking physician-prescribed glucocorticoids by the end of the 3 yr study period. The patients in the prednisolone group were commenced on this treatment at some time during the 6 months following withdrawal of study treatment. Both groups of patients increased their weight during the 36 months of the trial. There was no significant difference between groups for change in weight at 2 yr; however, in the third year the prednisolone group lost an average of 3.1 kg after prednisolone withdrawal (95% CI 1.9-4.3), whereas the placebo group continued to increase weight by 1.5 kg (95% CI 0.3-2.7). There were no significant changes in blood pressure. Joint destruction in rheumatoid arthritis, measured here by the Larsen index and the proportion of hands with erosions, is arguably the most important objective was an early additional benefit for the steroid-treated patients for pain, disability and joint inflammation parameter to modify with treatment [3] . We have already shown that fixed daily doses of 7.5 mg of prednisolone compared to that in the placebo patients, but there were no significant differences between the groups in for 2 yr will significantly reduce progression of the Larsen index and the proportion of hands which develop their any of the clinical measures after 9 months. A specific analysis of changes between 24 and 27 months, immedifirst erosions in patients with early disease [4] . This double-blind radiographic follow-up study has shown ately following withdrawal of trial medication, is shown in Table IV . The only evidence for a flare in clinical that after prednisolone withdrawal there is significant deterioration in the Larsen index, even though the majorsymptoms is a relative increase in the articular index in the prednisolone-treated patients, but the difference ity of patients continued to take specific anti-rheumatoid treatment. This reinforces the conclusion that prednisobetween the two groups is due primarily to a (possibly chance) reduction in the joint inflammation in the lone is able to suppress erosive progression, but suggests it is only able to do so if it continues to be taken. It is placebo group ( Fig. 2) . Neither group showed any significant change in their pain assessments at 30, 33 possible that the co-prescribed drugs have reinforced the effect of glucocorticoids, but the design of this trial did or 36 months compared to that at 24 months, and there were no significant differences between the groups not address that issue. There is no suggestion from the results that there is in this respect. There was no significant change in the Z-scores for acute-phase response in the third year an 'overshoot' of radiographic progression once glucocorticoids are withdrawn. Rather, the rate of progress either within or between groups.
There was no change in the proportion of patients runs a little less than and approximately parallel to that of the first year of placebo treatment, and shows taking various anti-rheumatoid drugs during the third year in either group ( Table V ) . In addition, there was that glucocorticoid treatment postpones the progression in Larsen score which would otherwise have no difference in the outcome measurements amongst the placebo group whether they received antioccurred. At the end of the 3 yr follow-up, patients who had been treated with prednisolone for 2 yr still rheumatoid drugs or not, and the proportion of co-prescribed drugs was the same in patients included had significantly lower Larsen scores than did placebotreated patients. and excluded from the X-ray analysis (data not shown).
A small number of patients were treated with sysThe development of erosions in hands which had no erosions at baseline was suppressed during prednisolone temic glucocorticoids by their managing physician ( Table VI ) . Overall, five of the original prednisolone treatment and progressed at a much slower rate than in the placebo-treated patients. In the year following withgroup patients and six of the original placebo group 
Pred, prednisolone; NSAID, non-steroidal anti-inflammatory drug; Plac, placebo; SARD, specific anti-rheumatoid drug; Diff, difference. drawal of prednisolone, only a further 5% of hands toms (pain, disability) and signs (articular index) of joint inflammation did not change after withdrawal of became erosive, which was not significantly different from the rate on treatment. This raises the possibility glucocorticoid treatment, but joint damage did progress. This mirrors the finding in the original study [4] that treatment for 2 yr with prednisolone may have a longer lasting effect in the prevention of onset of erowhere symptomatic improvement from glucocorticoids lasted for only a short time, but suppression of radiosions. A recent randomized controlled trial of 155 patients treated with higher doses of prednisolone, but graphic progression lasted throughout the 2 yr of treatment. Although the radiographic results relate only to for only 6 months [11], has also shown a reduction in the rate of radiological progression, with some stronger the hand, these findings argue in favour of the existence of two pathological processes taking place within the evidence that the benefits of prednisolone may persist after treatment is withdrawn. A longer term radiographic joint-inflammation and joint destruction-which respond differently to treatment. follow-up of patients after the end of treatment would be worthwhile. We have not calculated the number of Eleven previous studies have been published which contribute evidence on the effects of glucocorticoids in 'erosive patients' by combining the presence of erosions in both hands because we have no information about rheumatoid arthritis ( Table VII ) . Eight [4, 11-14, 17, 18, 20] are randomized controlled trials and one [16 ] erosions at other joint sites such as the feet.
Many clinicians are concerned about the possibility of is a longer term follow-up of one of these studies. Six of these eight are trials of daily oral glucocorticoids a deleterious flare in clinical signs and symptoms after glucocorticoid treatment is withdrawn. The clinical which point to a reduction in erosive progression. The two studies which do not support such a conclusion assessments in this study did not show any consistent deterioration at 27 or 30 months following glucocorti- [17, 20] were tests of monthly i.v. infusion of methylprednisolone for 6 or 12 months. The results of the coid withdrawal at 24 months, but a small number of patients were started on treatment with glucocorticoids present study, which show that erosive progression recommences once glucocorticoid treatment is withby their managing physician during this time or in the following 3 months. This suggests that the way in which drawn, reinforce these findings. How long glucocorticoids might best be prescribed for the treatment of treatment was scaled down (alternate days for 2 weeks and every third day for 2 weeks) was clinically acceptable relatively early rheumatoid arthritis cannot be determined from this study, and the control of erosive to most patients. Many investigators noticed that there were some patients who experienced worse symptoms progression will need to be balanced against the potential long-term risk of adverse reaction, recently for a shorter period than 3 months, but this was not formally assessed in this study. The total number of reviewed by Saag et al. [21] . Measurements of bone mineral density (BMD) in the lumbar spine and fempatients on treatment with systemic glucocorticoids was similar in the prednisolone and placebo groups at the oral neck by dual-energy X-ray absorptiometry have been reported for 24 patients in this study during the end of the follow-up period.
An important finding in this study is that the symptreatment phase [22] . After 1 yr, BMD was reduced 
